Veru Inc is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of diseases, particularly in the areas of oncology and urology. The company is engaged in the research and development of novel drug candidates aimed at addressing unmet medical needs, with a strong emphasis on advancing therapies for prostate cancer and other challenging health conditions. Veru is also involved in the production of specialty pharmaceutical products, showcasing its commitment to improving patient outcomes through scientific innovation and rigorous clinical trials.
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
PALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - The demand for antiviral drugs has been increasing globally due to the growing prevalence of viral diseases. Customers are increasingly seeking antiviral drugs that are effective against a wide range of viruses and have minimal side effects. They also prefer drugs that are easy to administer and have a shorter treatment duration. The Antiviral Drugs segment is expected to experience significant growth, which is mainly driven by the testing of novel treatments for COVID-19. There are also more general drivers of the market: the rising number of HIV cases worldwide and the need for continuous development in the field of antiviral drugs. A report from Statista said that: “The projected revenue in the Antiviral Drugs market worldwide is estimated to reach US$51.18bn in 2024. It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.58%, leading to a market volume of US$55.36bn by 2029. In terms of global comparison, United States is anticipated to generate the highest revenue, with US$30,640.00m in 2024. In the worldwide market for antiviral drugs, the United States leads in research and development, driving innovation and setting industry standards.” Active Biotechs in the biotech markets today include: NanoViricides, Inc. (NYSE: NNVC), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Veru Inc. (NASDAQ: VERU), Chimerix (NASDAQ: CMRX), SIGA Technologies, Inc. (NASDAQ: SIGA).
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Within the vibrant domain of healthcare stocks, innovation and collaborative efforts are shaping the industry's panorama. Here, we present a glimpse of noteworthy advancements. The healthcare sector has attracted substantial interest from investors, prompting a concise examination of five healthcare stocks currently priced at less than $1 per share.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Veru Inc. (NASDAQ: VERU) on behalf of long-term stockholders following a class action complaint that was filed against Veru on December 5, 2022 with a Class Period from May 11, 2022 to November 9, 2022. Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Veru Inc. (NasdaqCM: VERU).
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
